Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Therapeutic Potential of Bromodomain and Extra-Terminal Domain Inhibitors for Synovial Sarcoma Cells

11 Mar 2024

Abstract excerpt

Synovial sarcoma (SS), a rare subtype of soft-tissue sarcoma distinguished by expression of the fusion gene SS18-SSX, predominantly affects the extremities of young patients. Existing anticancer drugs have limited efficacy against this malignancy, necessitating the development of innovative therapeutic approaches. Given the established role of SS18-SSX in epigenetic regulation, we focused on bromodomain and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related gene regulation
Share to Multiple Myeloma Research and Treatments
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38539460
DOI: 10.3390/cancers16061125

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Therapeutic Potential of Bromodomain and Extra-Terminal Domain Inhibitors for Synovial Sarcoma CellsPMID 38539460Read ↗

ATR Is a Therapeutic Target in Synovial SarcomaSemantic proximity Read ↗

Genetic and Molecular Heterogeneity of Synovial Sarcoma and Associated Challenges in TherapySemantic proximity Read ↗

Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcomaSemantic proximity Read ↗

Innovative Breakthroughs for the Treatment of Advanced and Metastatic Synovial SarcomaSemantic proximity Read ↗

Molecular Profiling Defines Three Subtypes of Synovial SarcomaSemantic proximity Read ↗

Molecular and epigenetic oncogenesis in synovial sarcoma: implications for cancer biology, diagnosis and treatmentSemantic proximity Read ↗

Targeting of SUMOylation leads to cBAF complex stabilization and disruption of the SS18::SSX transcriptome in Synovial SarcomaSemantic proximity Read ↗

DNA demethylating agents suppress preclinical models of synovial sarcomaSemantic proximity Read ↗

Opposing immune and genetic forces shape oncogenic programs in synovial sarcomaSemantic proximity Read ↗

Integrative multi-omics analysis reveals molecular subtypes and tumor evolution of synovial sarcomaSemantic proximity Read ↗

Targeting of SUMOylation leads to cBAF complex stabilization and disruption of the SS18::SSX transcriptome in Synovial SarcomaSemantic proximity Read ↗

Synovial Sarcoma Preclinical Modeling: Integrating Transgenic Mouse Models and Patient-Derived Models for Translational ResearchSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.